Cargando…

Independent endpoint event review for the elimination of reporting bias in an open label phase III pharmaceutical trial

Detalles Bibliográficos
Autores principales:	Hall, Peter, Waterhouse, Anna, Smith, Isabelle, Brown, Julia, Gregory, Walter, Steger, Guenther, Bell, Richard, Cameron, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4660158/ http://dx.doi.org/10.1186/1745-6215-16-S2-P188

Ejemplares similares

Eliminating bias/living with bias?
por: Chapman, Jens
Publicado: (2012)

Eliminating unintended bias in personalized policies using bias-eliminating adapted trees (BEAT)
por: Ascarza, Eva, et al.
Publicado: (2022)

Verifying Elimination Programs with a Special Emphasis on Cysticercosis Endpoints and Postelimination Surveillance
por: Handali, Sukwan, et al.
Publicado: (2012)

A Multicenter Evaluation of Diagnostic Tools to Define Endpoints for Programs to Eliminate Bancroftian Filariasis
por: Gass, Katherine, et al.
Publicado: (2012)

Eliminating bias: a routine commitment
por: Regional Health– Europe, The Lancet
Publicado: (2022)

Protocol of controlled odorant stimulation for reducing apnoeic episodes in premature newborns: a randomised open-label Latin-square study with independent evaluation of the main endpoint (PREMODEUR)
por: Duchamp-Viret, Patricia, et al.
Publicado: (2021)

Comparison of an ordinal endpoint to time-to-event, longitudinal, and binary endpoints for use in evaluating treatments for severe influenza requiring hospitalization
por: Peterson, Ross L., et al.
Publicado: (2019)

Blinded continuous monitoring in clinical trials with recurrent event endpoints
por: Friede, Tim, et al.
Publicado: (2018)

Ascertainment Bias in TB Treatment Trials: Can Systematic Assessment of Objective Endpoints Solve It?
por: Mitnick, Carole D., et al.
Publicado: (2023)

Weighted composite time to event endpoints with recurrent events: comparison of three analytical approaches
por: Ozga, Ann-Kathrin, et al.
Publicado: (2022)

GI-REASONS: A Novel 6-Month, Prospective, Randomized, Open-Label, Blinded Endpoint (PROBE) Trial
por: Cryer, Byron, et al.
Publicado: (2013)

Potential bias in ophthalmic pharmaceutical clinical trials
por: Varner, Paul
Publicado: (2008)

Eliminating viscosity bias in lateral flow tests
por: Kainz, Daniel M., et al.
Publicado: (2021)

A systematic comparison of recurrent event models for application to composite endpoints
por: Ozga, Ann-Kathrin, et al.
Publicado: (2018)

Patient recruitment strategies for adaptive enrichment designs with time-to-event endpoints
por: Uozumi, Ryuji, et al.
Publicado: (2019)

Methods for safety and endpoint ascertainment: identification of adverse events through scrutiny of negatively adjudicated events
por: Fanaroff, Alexander C., et al.
Publicado: (2020)

Pharmaceutical excipients and the information on drug labels
por: Balbani, Aracy Pereira Silveira, et al.
Publicado: (2015)

Effects of immunoglobulin plus prednisolone in reducing coronary artery lesions in patients with Kawasaki disease: study protocol for a phase III multicenter, open-label, blinded-endpoints randomized controlled trial
por: Lin, Si-Yuan, et al.
Publicado: (2021)

Future prospects for dissecting inter-individual variability in the absorption, distribution and elimination of plant bioactives of relevance for cardiometabolic endpoints
por: Landberg, Rikard, et al.
Publicado: (2019)

Endpoints used in phase III randomized controlled trials of treatment options for COVID-19
por: Desai, Aakash, et al.
Publicado: (2020)

Surrogate endpoints.
por: Ellenberg, S. S.
Publicado: (1993)

The Keynesian Endpoint
por: Crescenzi, Tony
Publicado: (2010)

Endpoint security
por: Kadrich, Mark
Publicado: (2007)

Randomized gates eliminate bias in sort‐seq assays
por: Trippe, Brian L., et al.
Publicado: (2022)

A novel event-free survival endpoint in locally advanced pancreatic cancer
por: Hammel, Pascal, et al.
Publicado: (2021)

Comparison of primary endpoints between publications, registries, and protocols of phase III cancer clinical trials
por: Liang, Fei, et al.
Publicado: (2017)

Efficient analysis of time-to-event endpoints when the event involves a continuous variable crossing a threshold
por: Lin, Chien-Ju, et al.
Publicado: (2020)

Accounting for dropout in xenografted tumour efficacy studies: integrated endpoint analysis, reduced bias and better use of animals
por: Martin, Emma C., et al.
Publicado: (2016)

Obesity, the Endocannabinoid System, and Bias Arising from Pharmaceutical Sponsorship
por: McPartland, John M.
Publicado: (2009)

Gender bias in clinical research, pharmaceutical marketing, and the prescription of drugs
por: Chilet-Rosell, Elisa
Publicado: (2014)

Towards Eliminating Bias in Cluster Analysis of TB Genotyped Data
por: van Schalkwyk, Cari, et al.
Publicado: (2012)

Mixed response and time-to-event endpoints for multistage single-arm phase II design
por: Lai, Xin, et al.
Publicado: (2015)

Estimation in multi‐arm two‐stage trials with treatment selection and time‐to‐event endpoint
por: Brückner, Matthias, et al.
Publicado: (2017)

Critical design considerations for time-to-event endpoints in amyotrophic lateral sclerosis clinical trials
por: van Eijk, Ruben P A, et al.
Publicado: (2019)

Pitfall in the Design and Analysis of Comparative Oncology Trials With a Time-to-Event Endpoint and Recommendations
por: McCaw, Zachary R, et al.
Publicado: (2022)

INSP-04. Confirmatory adaptive designs for survival trials with several time-to-event endpoints
por: Schmidt, Rene
Publicado: (2022)

The New York Medical Independent and Pharmaceutical Reporter
Publicado: (1864)

The evaluation of surrogate endpoints
por: Burzykowski, Tomasz, et al.
Publicado: (2005)

Surrogate Endpoints in Medicine
por: Srivastava, Sudhir, et al.
Publicado: (2002)

Choroideremia: The Endpoint Endgame
por: Abdalla Elsayed, Maram E. A., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_psm8kanmpmjnadee0mjc03kclq